All In Biotech

Drug Trial Radar · NCT02058368

Study to Compare the Efficacy and Safety of Combination Treatment With Dutasteride and Tamsulosin With Tamsulosin Monotherapy, in Men With Moderate to Severe Benign Prostatic Hyperplasia

A Randomized, Double-blind, Parallel Group Study to Compare the Efficacy and Safety of Combination Treatment With Dutasteride (0.5mg) and Tamsulosin (0.2mg) With Tamsulosin (0.2mg) Monotherapy, Administered Once Daily for 2 Years, on the Improvement of Symptoms and Health Outcomes in Men With Moderate to Severe Benign Prostatic Hyperplasia

Last checked: Nov 20, 2026Latest source record: Apr 5, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 607 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

607

Actual

Start

Feb 10, 2014

Primary completion

Mar 3, 2017

Study completion Mar 3, 2017

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Feb 10, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
Male only, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicentre, randomised, double-blind, parallel group study in Asian subjects. The aim of the study is to investigate whether combination therapy with dutasteride and tamsulosin is more effective than tamsulosin monotherapy for the improvement of symptoms and health outcomes in an at risk population of benign prostatic hyperplasia (BPH) clinical progression including older men (\>=50 years), with moderate-severe symptoms of BPH, enlarged prostates (\>=30 cubicentimeter \[cc\]) and prostate specific antigen (PSA) \>= 1.5 nanograms per milliliter (ng/mL). Each subject who met the eligibility criteria at screening will enter a four-week single-blind, placebo run-in period following which each subject will be randomised into a 2 year double-blind treatment phase. The total study duration for each subject will be up to 110 weeks.

Conditions

  • Prostatic Hyperplasia

Interventions

  • Dutasteride 0.5mg capsulesDrug

    Dutasteride 0.5mg capsules will be supplied as plain, oblong, opaque, dull yellow soft gelatin capsules.

  • Dutasteride placebo capsulesDrug

    Dutasteride placebo will be supplied as plain, oblong, opaque, dull yellow soft gelatin capsules.

  • Tamsulosin 0.2mg tabletsDrug

    Commercially available tamsulosin 0.2mg tablets will be supplied.

  • Disintegrating placebo tamsulosin tabletDrug

    Disintegrating placebo tamsulosin tablet will be supplied for the run-in period.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in International Prostate Symptom Score (IPSS) by Last Observation Carried Forward (LOCF) Approach at 24 MonthsTime frame: Baseline and 3, 6, 9, 12, 15, 18, 21 and 24 months

Locations

46 sites in 4 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Beijing, China

  • GSK Investigational Site

    Beijing, China

  • GSK Investigational Site

    Beijing, China

  • GSK Investigational Site

    Chongqing, China

  • GSK Investigational Site

    Shanghai, China

  • GSK Investigational Site

    Shanghai, China

  • GSK Investigational Site

    Shanghai, China

  • GSK Investigational Site

    Shanghai, China

  • GSK Investigational Site

    Shanghai, China

  • GSK Investigational Site

    Xiame, Fujian, China

  • GSK Investigational Site

    Guangzhou, Guangdong, China

  • GSK Investigational Site

    Wuhan, Hubei, China

  • GSK Investigational Site

    Suzhou, Jiangsu, China

  • GSK Investigational Site

    Shenyang, Liaoning, China

  • GSK Investigational Site

    Hangzhou, Zhejiang, China

  • GSK Investigational Site

    Fukuoka, Japan

  • GSK Investigational Site

    Fukuoka, Japan

  • GSK Investigational Site

    Hyōgo, Japan

  • GSK Investigational Site

    Kanagawa, Japan

  • GSK Investigational Site

    Kanagawa, Japan

  • GSK Investigational Site

    Ōita, Japan

  • GSK Investigational Site

    Osaka, Japan

  • GSK Investigational Site

    Saitama, Japan

  • GSK Investigational Site

    Tokyo, Japan

  • GSK Investigational Site

    Tokyo, Japan

  • GSK Investigational Site

    Yamanashi, Japan

  • GSK Investigational Site

    Busan, South Korea

  • GSK Investigational Site

    Daegu, South Korea

  • GSK Investigational Site

    Gwangju, South Korea

  • GSK Investigational Site

    Incheon, South Korea

  • GSK Investigational Site

    Jeonju, South Korea

  • GSK Investigational Site

    Seoul, South Korea

  • GSK Investigational Site

    Seoul, South Korea

  • GSK Investigational Site

    Seoul, South Korea

  • GSK Investigational Site

    Seoul, South Korea

  • GSK Investigational Site

    Seoul, South Korea

  • GSK Investigational Site

    Seoul, South Korea

  • GSK Investigational Site

    Seoul, South Korea

  • GSK Investigational Site

    Chiayi City, Taiwan

  • GSK Investigational Site

    Hualien City, Taiwan

Showing 40 of 46 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.